<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650622</url>
  </required_header>
  <id_info>
    <org_study_id>STU 112014-001</org_study_id>
    <nct_id>NCT02650622</nct_id>
  </id_info>
  <brief_title>Genetic and Metabolic Disease in Children</brief_title>
  <official_title>Genetic Regulators of Metabolism and Development in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized, non-blinded observational study. The overarching goal
      is to discover new disease-associated genes in children, while establishing a specific focus
      on disorders where molecular characterization is most likely to lead to novel therapies. This
      study will merge detailed phenotypic characterization of patients presenting to the Pediatric
      Genetics and Metabolism Division in the Department of Pediatrics/Children's Medical Center at
      Dallas and collaborating clinics with Next-Generation sequencing techniques to identify
      disease-producing mutations. The primary objective of the study is to identify novel
      pathogenic mutations in children with rare Mendelian disorders. A secondary objective of the
      study is to establish normative ranges of a large number of metabolites from healthy newborns
      and older children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Discovery of genetic basis of impaired metabolism has greatly advanced treatment of patients
      with known metabolic diseases. However, many more genetic and metabolic disorders and their
      molecular causes remain to be discovered. The overall goal of this study is to discover new
      disease-associated genes in children, while establishing a specific focus on metabolic
      disorders where molecular characterization is most likely to lead to novel therapies. The
      primary objective is to identify novel pathogenic mutations in children with rare Mendelian
      disorders. The secondary objectives are: 1) Optimize methodology for metabolomic sample
      collection, processing and analysis; and 2) Establish normative ranges for a large number
      (potentially up to 1000) of metabolites in healthy newborns and older children.

      Approximately one in three admissions to tertiary care pediatric hospitals results from
      conditions with a genetic basis. Although the majority of these conditions are rare, they
      collectively account for a disproportionate amount of illness and death in children.
      Discovery of the genetic basis of rare conditions often uncovers the pathophysiological basis
      of common diseases. This is particularly true for genetic diseases of impaired metabolism
      (inborn errors of metabolism, IEMs). There are many more genetic and metabolic disorders yet
      to be discovered. Of approximately 20,000 known human genes, less than one-fifth are
      currently associated with a disease phenotype. IEMs are a particular area of focus for us for
      two major reasons. First, of the several hundred known IEMs, many are already effectively
      treated with dietary modifications and/or medical therapy. This indicates to us that
      discovery of new IEM genes has great potential to produce clinically actionable insights into
      pathophysiology and therapeutic opportunities, ultimately leading to treatment of children
      that would otherwise be impossible to treat. Second, the PI of this study, Dr. Ralph
      DeBerardinis, is an expert in metabolomics, the practice of identifying and quantifying
      metabolites from biological systems. We will therefore implement research-based metabolomic
      profiling to the evaluation of patients with suspected IEMs or other genetic diseases. This
      detailed analysis will substantially increase the likelihood of identifying clinically
      relevant metabolic perturbations in children with growth failure, acidosis, hypoglycemia,
      hyperammonemia, and other abnormalities of putative genetic origin. It would also enable us
      to interpret mutations uncovered by clinical or research-based genomic sequencing. We believe
      that establishing a systematic procedure to evaluate both the metabolome and the genome in
      sick children will produce new insights into the genetic basis of pediatric disease, and
      ultimately new ways to treat these conditions.

      In this study, subjects will be recruited as two populations: control and diseased. In the
      control population, plasma samples of healthy newborns will be acquired at the time of blood
      collection for state-mandated newborn screening from Parkland. We will also collect blood
      from healthy children from the clinics at Children's Medical Center (CMC), again piggybacking
      this research sample with venipuncture for clinically indicated blood collection. All plasma
      samples will be subjected to metabolomics to determine the healthy ranges for a large number
      of metabolites. This comprehensive profile of metabolites in children will be used as
      normative ranges to identify outlying metabolites in diseased subjects. Additionally, if
      suspected metabolic outliers are detected from this normal population, DNA samples extracted
      from the leftover packed cells or blood samples will be subjected to genomic sequencing to
      profile the associated gene mutations. The diseased population will be recruited from the
      clinics of the Pediatric Genetics and Metabolism Division in the Department of
      Pediatrics/CMC. Blood and DNA samples will be collected from patients for metabolomic
      analysis and next-generation sequencing respectively to define the metabolic abnormalities
      and associated gene mutations. Skin fibroblasts from patients will also be collected and used
      for biological validation of the metabolic effects of novel mutations, in particular by
      complementing diseased fibroblasts with wild-type alleles of genes mutated in the patient. If
      any rare Mendelian disorder is considered in a subject, blood from his/her family members
      will be acquired and subjected to metabolomic and genomic analyses to facilitate
      identification of the diseased-associated genes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perform metabolomic profiling and exome sequencing in children with presumed genetic and metabolic diseases</measure>
    <time_frame>3-4 years</time_frame>
    <description>The Levels of the metabolites that can be detected in the plasma from the enrolled children will be measured by mass-spectrometry technique.The DNA samples will be extracted from the blood samples of diseased children and then subjected to exome sequencing to identify gene mutations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perform metabolomic profiling in healthy children</measure>
    <time_frame>3-4 years</time_frame>
    <description>The Levels of the metabolites will be measured by by mass-spectrometry technique in the plasma samples from enrolled healthy children.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Establish a specimen repository of healthy and diseased children</measure>
    <time_frame>3 years</time_frame>
    <description>Blood samples and derived plasma and DNA samples, and patient fibroblast cell lines will be de-identified and stored in research laboratory.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1550</enrollment>
  <condition>Genetic Diseases</condition>
  <condition>Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort 1-Newborns aged 1-2 days</arm_group_label>
    <description>No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2-Children aged 0-18 years</arm_group_label>
    <description>No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-Diseased childrens and families</arm_group_label>
    <description>Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin Biopsy</intervention_name>
    <description>Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.</description>
    <arm_group_label>Cohort 3-Diseased childrens and families</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      There are 3 cohorts in this study:

      Cohort 1: healthy newborns Cohort 2: healthy children aged 0-18 years old Cohort 3: Children
      with genetic/metabolic disorders and their families

      Blood samples will be collected from all the three cohorts for isolation of plasma for
      metabolomic analysis.

      In addition, DNA will be extracted from the blood samples of cohort 3 patients for genomic
      sequencing, and skin fibroblast cells will be collected from the proband patients in cohort
      3.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Two populations will be enrolled in this study, control and diseased. Healthy newborns and
        older children will be recruited into the control population from Parkland Postpartum units
        and Children's Medical Center (CMC), respectively. The diseased population will be
        recruited from the clinics of the Pediatric Genetics and Metabolism Division in the
        Department of Pediatrics of CMC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria of Cohort 1- Newborn:

          -  Subjects aged 1-2 days

          -  Subjects with gestational age 37-42 weeks

          -  Subjects with stable clinical status (admitted to normal newborn nursery)

        Inclusion criteria of Cohort 2 - Older children:

        â€¢ Subjects aged 0-18 years

        Inclusion criteria of Cohort 3 - Diseased children:

        Subjects (no age limit) with ANY phenotype as below:

          -  Confirmed metabolic or genetic diseases

          -  Suspected metabolic or genetic diseases

          -  Episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic
             acidosis)

          -  Developmental regression

          -  Major congenital malformation

          -  Other unexplained symptoms of potential genetic origin

        Exclusion criteria of Cohort 1 - Newborn:

          -  Subjects with gestational age &lt;37 weeks or &gt;42 weeks

          -  Subjects with overt signs of metabolic dysfunction, distress or genetic diseases
             including hypoglycemia, hyperglycemia, sepsis/shock, hypoxemia, or major congenital
             malformation

          -  Subjects with mothers whose pregnancies were complicated by gestational diabetes,
             gestational hyperglycemia, gestational hypertension, preeclampsia, or any other major
             disorders.

        Exclusion criteria of Cohort 2 - Older children:

          -  Subjects with confirmed metabolic or genetic diseases

          -  Subjects with suspected metabolic or genetic diseases

          -  Subjects with episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia,
             metabolic acidosis)

          -  Subjects with developmental regression

          -  Subjects with major congenital malformation

        Exclusion criteria of Cohort 3 - Diseased children No.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph J DeBerardinis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center, Children's Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Ni, PhD</last_name>
    <phone>2146482189</phone>
    <email>min.ni@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donnice Michel</last_name>
      <phone>214-456-6148</phone>
      <email>DONNICE.MICHEL@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Ralph J DeBerardinis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Scriver CR, Neal JL, Saginur R, Clow A. The frequency of genetic disease and congenital malformation among patients in a pediatric hospital. Can Med Assoc J. 1973 May 5;108(9):1111-5.</citation>
    <PMID>4704890</PMID>
  </results_reference>
  <results_reference>
    <citation>Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA, Shendure J, Bamshad MJ. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010 Jan;42(1):30-5. doi: 10.1038/ng.499. Epub 2009 Nov 13.</citation>
    <PMID>19915526</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolism</keyword>
  <keyword>Genetics</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Genomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

